Correlia Biosystems

Correlia Biosystems develops a proteomics platform. Their first commercial platform is for rapid detection of protein biomarkers providing high resolution and granular data from research, drug development, diagnostics, and personalized medicine. Correlia is a company within JLABS, the external R&D and innovation arm of Johnson & Johnson.

The company was founded at UC Berkeley from 2 post-docs and a graduate student from the Herr Lab. The core technology they developed enabled rapid quantification of protein biomarker panels in under 15 min from only 2 microliters of sample. Correlia Biosystems uses microfluidics and integrates assays such as ELISA and other immunoassays into rapid, automated and portable platforms for pharm and diagnostic applications.

Correlia received an NIH Small Business Innovation Research Grant in 2014 for the development of an electrokinetic lateral flow test (left) for diagnosing sickle cell disease and trait. The device is designed to be used at the point-of-care in work in low resource settings. The company collaborated with the Sickl Cell Foundation of Ghana on the project.

Correlia launched in the inaugural class of the Foundry incubator at UC Berkeley. During this time they were able to secure grants from the NIH, NSF, and other sources totaling $875K which was used to develop the core technology for commercial use. In 2018, Correlia participated in the Y Combinator W2018 cohort to launch a seed fundraising round.